Tigertriever Distal Vessels Registry

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

9 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-07

Study Completion Date

2023-10-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A registry study to collect data on the Tigertriever device at restoring blood flow by removing clots in M2 or distal vessels in patients experiencing acute ischemic stroke, during commercial use.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

JETi Lower Extremity Arterial Thrombosis

NCT04370691

Arterial Thrombosis

COMPLETED

Study of a Novel Thrombectomy Device to Treat Acute Iliofemoral Deep Venous Thrombosis

NCT02414802

Venous Thrombosis

UNKNOWN NA

Endovascular Therapy in Patients With Acute Deep Vein Thrombosis

NCT05827120

Acute Deep Venous Thrombosis

COMPLETED

JETi Lower Extremity Venous Thrombosis

NCT07027878

Venous Thrombosis

ACTIVE_NOT_RECRUITING

Radial, Sequential Compression Device Deep Venous Thrombosis Detection Study

NCT04232501

Deep Venous Thrombosis

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tigertriever

Male or female patients (age ≥18) who present with an acute ischemic stroke due to a M2 or distal (medium to small) vessel occlusion confirmed by vessel imaging and treated with the Tigertriever 17 or 13 revascularization devices.

Tigertriever

Intervention Type DEVICE

Mechanical Thrombectomy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tigertriever

Mechanical Thrombectomy

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who present with acute ischemic stroke, who can be treated within 6 hours of symptoms onset, who are either refractory to or ineligible for IV t-PA treatment and intend to be treated with thrombectomy.
* Patients ≥18
* NIHSS Score of ≥2
* Angiographically confirmed occlusion in a M2 or distal (medium to small) branch that is accessible to the Tigertriever device (17 or 13) as determined by the vessel diameter (≥1mm).
* Anticipated life expectancy of at least 6 months from presentation
* Signed informed consent form by the patient or a legally acceptable representative.

Exclusion Criteria

* Extended infarct - ischemic changes \>1/3 MCA territory / 100 ml tissue or ASPECT score \<5

* Pre- stroke mRS ≥ 2
* Unknown time of stroke symptom onset
* Vessel diameter \< 1mm
* Angiographically evident extreme vessel tortuosity that may preclude the device from reaching the target area.
* Occlusion/stenosis proximal to thrombus that precludes safe retrieval
* Medical co-morbidities including but not limited to:
* Uncontrolled coagulopathy such as International Normalized Ratio (INR) of \> 3.0 or platelets count \< 40 x109/L or APTT \>50 sec
* Serious concurrent medical illness: myocardial infarction, seizures, sepsis, uncontrolled diabetes, uncontrolled hypertension, brain tumor, renal impairment (eGFR \<60).
* Baseline glucose \< 2.7 or \> 22.2 mmol/L
* Imaging features of:

* raised intracranial pressure or significant mass effect (for example, midline shift, severe sulcal effacement, transcompartmental herniation)
* intracranial hemorrhage
* vascular malformation or aneurysm
* significant vascular abnormality such as carotid dissection, complete carotid occlusion or large/medium vessel vasculitis
* Allergy/sensitivity to nickel-titanium or contrast media
* Females who are pregnant or lactating
* Unable to obtain informed consent from the patient or a suitable legal representative
* Any other contraindication to thrombectomy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No